Table 5 Adjusted odds ratios and 95% confidence interval for the associations between parity and breastfeeding and breast cancer subtypes overall and following re-classification of the luminal A-like subtype by p53 expression

From: Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression

Subtype

Parous/nulliparous

Parous vs. nulliparous

Ever/never

Ever vs. never breastfed

OR (95% CI)

P

OR (95% CI)

P

A-like (Overall)

2590/114

1.00 (reference)

 

2049/320

1.00 (reference)

 

B-like/HER2−

959/44

0.94 (0.65, 1.35)

0.75

720/127

0.89 (0.71, 1.11)

0.30

B-like/HER2+

775/33

1.17 (0.78, 1.75)

0.45

594/98

1.01 (0.78, 1.29)

0.96

HER2-enriched

386/16

1.15 (0.67, 1.98)

0.61

319/46

1.12 (0.80, 1.57)

0.50

TNBC

681/22

1.36 (0.85, 2.18)

0.20

518/69

1.18 (0.89, 1.57)

0.24

A-like/p53−

1152/63

1.00 (reference)

 

940/153

1.00 (reference)

 

A-like/p53+

858/20

2.67 (1.60, 4.51)

<0.01

637/80

1.38 (1.03, 1.85)

0.03

B-like/HER2− (overall)

 

1.25 (0.83, 1.87)

0.28

 

0.96 (0.74, 1.24)

0.74

B-like/HER2−/p53−

295/12

1.35 (0.71, 2.57)

0.35

229/35

1.08 (0.72, 1.61)

0.71

B-like/HER2−/p53+

415/23

1.06 (0.64, 1.75)

0.81

285/58

0.85 (0.61, 1.20)

0.36

B-like/HER2+ (overall)

 

1.56 (1.01, 2.43)

0.04

 

1.09 (0.82, 1.44)

0.55

B-like/HER2+/p53−

227/12

1.30 (0.68, 2.48)

0.43

180/32

0.99 (0.65, 1.51)

0.97

B-like/HER2+/p53+

341/16

1.37 (0.77, 2.44)

0.28

249/40

1.14 (0.78, 1.67)

0.50

HER2-enriched (overall)

 

1.55 (0.88, 2.75)

0.13

 

1.22 (0.85, 1.75)

0.28

HER2-enriched/p53−

92/6

1.03 (0.42, 2.49)

0.95

83/10

1.45 (0.73, 2.89)

0.29

HER2-enriched/p53+

169/8

1.32 (0.61, 2.84)

0.48

137/18

1.34 (0.79, 2.28)

0.27

TNBC (overall)

 

1.82 (1.10, 3.01)

0.02

 

1.28 (0.94, 1.74)

0.12

TNBC/p53−

210/7

1.69 (0.75, 3.79)

0.20

164/15

1.82 (1.03, 3.20)

0.04

TNBC/p53+

317/8

2.39 (1.12, 5.08)

0.02

243/30

1.37 (0.90, 2.09)

0.14

A-like/p53+

858/20

1.00 (reference)

 

637/80

1.00 (reference)

 

B-like/HER2− (overall)

 

0.47 (0.27, 0.80)

<0.01

 

0.69 (0.51, 0.94)

0.02

B-like/HER2−/p53−

295/12

0.50 (0.24, 1.05)

0.07

229/35

0.78 (0.51, 1.21)

0.27

B-like/HER2−/p53+

415/23

0.39 (0.21, 0.73)

<0.01

285/58

0.62 (0.43, 0.90)

0.01

B-like/HER2+ (overall)

 

0.58 (0.33, 1.03)

0.07

 

0.79 (0.57, 1.09)

0.15

B-like/HER2+/p53−

227/12

0.48 (0.23, 1.02)

0.06

180/32

0.72 (0.46, 1.13)

0.16

B-like/HER2+/p53+

341/16

0.51 (0.26, 1.01)

0.05

249/40

0.83 (0.55, 1.26)

0.38

HER2-enriched (overall)

 

0.58 (0.29, 1.14)

0.11

 

0.88 (0.60, 1.31)

0.54

HER2-enriched/p53−

92/6

0.38 (0.15, 0.99)

0.05

83/10

1.06 (0.52, 2.14)

0.88

HER2-enriched/p53+

169/8

0.49 (0.21, 1.15)

0.10

137/18

0.98 (0.56, 1.79)

0.93

TNBC (overall)

 

0.68 (0.36, 1.26)

0.22

 

0.93 (0.65, 1.31)

0.67

TNBC/p53−

210/7

0.63 (0.26, 1.53)

0.31

164/15

1.32 (0.74, 2.37)

0.35

TNBC/p53+

317/8

0.89 (0.38, 2.05)

0.78

243/30

0.99 (0.63, 1.57)

0.99

  1. Note: Odds ratios (OR) and 95% confidence intervals (CI) were obtained in multivariate polytomous logistic regression models mutually adjusted for parity or breastfeeding, age, age at menarche, BMI, family history of breast cancer
Back to article page